[{"orgOrder":0,"company":"Evgen Pharma","sponsor":"University Of Dundee","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"||Nrf2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evgen Pharma \/ University Of Dundee","highestDevelopmentStatusID":"9","companyTruncated":"Evgen Pharma \/ University Of Dundee"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Sulforaphane","moa":"||Nrf2","graph1":"Oncology","graph2":"Preclinical","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Evgen Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Evgen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lindus Health","sponsor":"Acinonyx Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2024","type":"Collaboration","leadProduct":"Alpha-Cyclodextrin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lindus Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindus Health \/ Acinonyx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lindus Health \/ Acinonyx Bio"}]

Find Clinical Drug Pipeline Developments & Deals for .alpha.-Cyclodextrin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lindus Health

                          Country arrow
                          Iran Expo
                          Not Confirmed

                          Lindus Health

                          Country arrow
                          Iran Expo
                          Not Confirmed

                          Details : The collaboration aims to conduct the clinical development of ACX, which is evaluating their topical cream's ability to treat patients with moderate to severe inflammatory acne.

                          Product Name : ACX

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Undisclosed

                          May 16, 2024

                          Lead Product(s) : Alpha-Cyclodextrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Acinonyx Bio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The net proceeds of the Fundraising are intended to be used to complete the formulation and scale up manufacturing of SFX-01 and other R&D nd general corporate purposes.

                          Product Name : SFX-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 02, 2021

                          Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $15.3 million

                          Deal Type : Public Offering

                          blank

                          03

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : A total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress.

                          Product Name : SFX-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 19, 2021

                          Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : University Of Dundee

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank